Clinical Evidence and Research Findings
British National Formulary Guidelines for Sildenafil
The British National Formulary (BNF) provides comprehensive guidance on sildenafil prescribing for erectile dysfunction. According to BNF recommendations, sildenafil is a first-line treatment option for ED, with established dosing protocols starting at 50mg approximately one hour before sexual activity. The BNF emphasises the importance of cardiovascular assessment before prescribing, particularly regarding contraindications with nitrate medications.
Landmark Clinical Trials and Efficacy Data
Sildenafil's effectiveness has been demonstrated in numerous randomised controlled trials involving thousands of participants. Clinical studies consistently show response rates of 60-85% across different patient populations, including men with diabetes, cardiovascular disease, and following prostate surgery. Research indicates that sildenafil improves erectile function scores significantly compared to placebo, with effects typically observed within 30-60 minutes and lasting up to 4-6 hours.
Long-term studies demonstrate sustained effectiveness over extended treatment periods, with many patients maintaining treatment response for several years. Research also shows that sildenafil can improve quality of life measures and relationship satisfaction scores in both patients and their partners.
Safety Profile and Adverse Events
Extensive safety data from clinical trials and post-marketing surveillance demonstrates sildenafil's generally well-tolerated profile when used appropriately. Common side effects reported in research include headache (16%), flushing (10%), and dyspepsia (7%). Most adverse events are mild to moderate and transient. Serious adverse events are rare when contraindications and drug interactions are properly observed.
Cardiovascular safety studies indicate that sildenafil is safe for men with stable cardiovascular disease, though careful assessment is required. Research shows no increased risk of cardiovascular events compared to placebo in appropriately selected patients.
Comparative Research: Generic vs Branded
Bioequivalence studies demonstrate that generic sildenafil provides identical therapeutic effects to branded Viagra. Research confirms that generic formulations contain the same active ingredient in equivalent concentrations, meeting strict regulatory standards for absorption and bioavailability. Patients can choose between generic sildenafil and branded Viagra based on personal preference, with both options available through EverydayMeds following clinical assessment.
Real-World Evidence and Effectiveness
Post-marketing studies and real-world evidence support sildenafil's clinical trial findings. Research from NHS prescription databases and patient registries confirms effectiveness across diverse patient populations in routine clinical practice. Studies show high treatment continuation rates, indicating patient satisfaction with treatment outcomes. Evidence suggests that early intervention with sildenafil may help prevent progression of erectile dysfunction in some cases.
